|
| Press Releases |
|
 |
|
| Wednesday, September 11, 2024 |
|
|
国泰君安国际获穆迪重申“Baa2” 长期发行人评级，展望“稳定” |
| 国泰君安国际控股有限公司（“国泰君安国际”、“公司”或“集团”，股份代号：1788.HK）宣布，国际信用评级机构穆迪更新对国泰君安国际的信贷评级报告，并重申国泰君安国际的“Baa2”长期发行人信用评级，展望保持“稳定”。 more info >> |
|
| Friday, September 6, 2024 |
|
|
GTJAI Receives Multiple Awards in Bond Connect 2024 Awards |
| Guotai Junan International Holdings Limited ('Guotai Junan International', the 'Company' or 'GTJAI', stock code: 1788.HK) announced that in the Bond Connect Company Limited 2024 Outstanding Participating Institutions and Individuals Awards, GTJAI won the 'Primary Market Pioneer (Underwriter)' award, and its subsidiary Guotai Junan Financial Products Limited and its employee Yiyan Zhu won the 'Northbound Outstanding Investment Bank' award and the 'Northbound Outstanding Individual' award, respectively, highlighting the Company's outstanding performance and significant contributions in various areas of Bond Connect (Northbound) business. more info >> |
|
|
國泰君安國際榮獲2024年度「債券通」多項殊榮 彰顯互聯互通業務實力 |
| more info >> |
|
|
国泰君安国际荣获2024年度“债券通”多项殊荣 彰显互联互通业务实力 |
| 国泰君安国际控股有限公司（“国泰君安国际”、“公司”或“集团”，股份代号：1788.HK）宣布，在债券通有限公司2024年度债券通优秀参与机构及个人评选中，国泰君安国际荣获了"一级市场创新机构（承销商）"奖项，子公司国泰君安金融产品有限公司及其员工朱一彦分别荣获"北向通优秀投资者（投资银行类）"、"北向通优秀个人"奖项，凸显了公司在债券通（北向通）业务各个领域的卓越表现和重要贡献。 more info >> |
|
| Wednesday, November 25, 2015 |
|
|
國泰君安證券股份有限公司與中國建設銀行股份有限公司達成全面戰略合作夥伴關係 |
日前，國泰君安國際（01788.HK）的控股公司國泰君安證券股份有限公司（「國泰君安」）與中國建設銀行股份有限公司簽署了全面戰略合作協議。
more info >> |
|
| Tuesday, September 3, 2024 |
|
|
GTJAI Once Again Receives Multiple Honors from Institutional Investor |
| Guotai Junan International Holdings Limited ('Guotai Junan International', the 'Company' or 'GTJAI', stock code: 1788.HK) announced that Institutional Investor, an international authoritative financial magazine, has announced the rankings for the "All-Asia Executive Team", recognizing outstanding companies in corporate management and investor relations. GTJAI stood out among 1,323 companies in 18 industries with outstanding performance, winning multiple awards in the banking and non-banking financial fields. In particular, the Company has been awarded as the "Most Honored Company" in Asia for the fourth consecutive year and has achieved impressive results in categories such as 'Best ESG' and 'Best Board of Directors', ranking among the top three in the industry. more info >> |
|
|
國泰君安國際再度榮獲《機構投資者》頒發多項殊榮 |
| 國泰君安國際控股有限公司（“國泰君安國際”、“公司”或“集團”，股份代號：1788.HK）宣佈，國際權威金融雜誌《機構投資者》（Institutional Investor）揭曉“亞洲最佳管理團隊”獲獎名單，表彰在企業管理和投資者關係工作中表現卓越的企業。國泰君安國際憑藉出色的表現，在18個行業領域1,323家公司中脫穎而出，榮獲銀行與非銀金融領域多項大獎。其中，公司連續第四年獲評為亞洲“最受尊敬企業”，並在“最佳ESG”及“最佳董事會”等類別評選中均獲得亮眼成績，位列行業前三位。 more info >> |
|
|
国泰君安国际再度荣获《机构投资者》颁发多项殊荣 |
| 国泰君安国际控股有限公司（“国泰君安国际”、“公司”或“集团”，股份代号：1788.HK）宣布，国际权威金融杂志《机构投资者》（Institutional Investor）揭晓“亚洲最佳管理团队”获奖名单，表彰在企业管理和投资者关系工作中表现卓越的企业。国泰君安国际凭借出色的表现，在18个行业领域1,323家公司中脱颖而出，荣获银行与非银金融领域多项大奖。其中，公司连续第四年获评为亚洲“最受尊敬企业”，并在“最佳ESG”及“最佳董事会”等类别评选中均获得亮眼成绩，位列行业前三位。 more info >> |
|
| Tuesday, August 27, 2024 |
|
|
GTJAI Announced 2024 Interim Results |
| GTJAI announced its interim results for the 6 months ended 30 June 2024. Although the global uncertainties continuously impacted the capital market in Hong Kong, the Group maintained stringent control over risks, vigorously enhanced its comprehensive financial service capabilities and product diversification driven by client demand, achieved an outstanding performance with revenue and profit achieved an overall increase, revenue increased significantly by 41% YOY to HK$2,171m, profit attributable to ordinary equity holders increased significantly by 63% YOY to HK$195m. more info >> |
|
|
國泰君安國際公佈2024年中期業績 |
| 國泰君安國際公佈2024年中期業績，儘管環球多重不確定性因素持續影響香港資本市場，集團嚴格把控風險，以客戶需求為出發點大力提升綜合性金融服務能力和產品多元化，實現了收入利潤全面上升，收入同比大幅上升41%達21.71億港元，普通股股東應佔溢利同比大幅增長63%達1.95億港元的佳績。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 11, 2024 14:45 JST
|
|
|
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership
Dec 11, 2024 12:06: JST
|
|
|
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership
Dec 11, 2024 11:06 HKT/SGT
|
|
|
雲頂新耀：加速腎病領域創新 邁向全球生物製藥領先地位
Dec 11, 2024 11:02 HKT/SGT
|
|
|
富士通、東洋大学、ココロバランス研究所、適切な対応の習得を支援するカスタマーハラスメント体験AIツールを活用した教育プログラムの実証実験を開始
Dec 11, 2024 11:00: JST
|
|
|
云顶新耀：加速肾病领域创新 迈向全球生物制药领先地位
Dec 11, 2024 10:56 HKT/SGT
|
|
|
FxPro Group Announces the Launch of BankPro: A Private Digital Banking Solution
Dec 11, 2024 10:00: JST
|
|
|
CELH Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Celsius Holdings, Inc. Investors of Securities Fraud Class Action Lawsuit Deadline
Dec 11, 2024 10:19 JST
|
|
|
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Wolfspeed, Inc.
Dec 11, 2024 10:15 JST
|
|
|
Combating customer harassment: Fujitsu, Toyo University and Kokoro Balance Research Institute launch field trial on AI-powered training program
Dec 11, 2024 10:11 JST
|
|
|
PACS Group, Inc. Investors: January 13, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Dec 11, 2024 10:10 JST
|
|
|
Acadia Healthcare Company, Inc. (ACHC) Investors: December 16, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Dec 11, 2024 10:05 JST
|
|
|
FxPro Group Announces the Launch of BankPro: A Private Digital Banking Solution
Dec 11, 2024 09:00 HKT/SGT
|
|
|
Photon Academy Unveils Solutions for Singapore's Growing Need for Evolving IB Tuition
Dec 11, 2024 09:00: JST
|
|
|
Photon Academy Unveils Solutions for Singapore's Growing Need for Evolving IB Tuition
Dec 11, 2024 08:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
